Ronald E Blaylock insider trades: Pfizer (PFE) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Ronald reports to the SEC
and 1 more company
Open-market buys and sales
18 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026 | PFE | ↑ Buy | 39,231 | $25.46 | $999K | Direct | Aug 5, 2026 (0d) |
| Feb 13, 2025 | PFE | ↑ Buy | 19,457 | $25.65 | $499K | Direct | Feb 14, 2025 (1d) |
| Jul 16, 2021 | KMX | ↓ Sell | 12,500 | $132.02 | $1.7M | Direct | Jul 20, 2021 (4d) |
| Aug 6, 2020 | PFE | ↑ Buy | 13,000 | $38.55 | $501K | Direct | Aug 10, 2020 (4d) |
| Jul 13, 2020 | KMX | ↓ Sell | 10,200 | $89.37 | $912K | Direct | Jul 15, 2020 (2d) |
| Sep 24, 2015 | ROIA | ↓ Sell | 10,000 | $2.45 | $25K | Direct | Sep 25, 2015 (1d) |
| Sep 23, 2015 | ROIA | ↓ Sell | 3,501 | $2.64 | $9K | Direct | Sep 24, 2015 (1d) |
| Jul 9, 2015 | KMX | ↓ Sell | 2,616 | $66.42 | $174K | Direct | Jul 13, 2015 (4d) |
| Jan 7, 2015 | KMX | ↓ Sell | 9,000 | $64.61 | $581K | Direct | Jan 9, 2015 (2d) |
| Apr 16, 2013 | KMX | ↑ Buy | 700 | $42.40 | $30K | Direct | Apr 17, 2013 (1d) |
| Jan 5, 2012 | KMX | ↓ Sell | 10,829 | $30.06 | $326K | Direct | Jan 6, 2012 (1d) |
| Dec 23, 2011 | KMX | ↓ Sell | 8,110 | $30.01 | $243K | Direct | Dec 27, 2011 (4d) |
| Apr 27, 2011 | WRB | ↓ Sell | 5,500 | $32.01 | $176K | Direct | Apr 28, 2011 (1d) |
| Oct 26, 2010 | KMX | ↓ Sell | 8,975 | $29.83 | $268K | Direct | Oct 27, 2010 (1d) |
| Sep 28, 2010 | WRB | ↓ Sell | 2,000 | $26.96 | $54K | Direct | Sep 30, 2010 (2d) |
| Dec 9, 2009 | GVSS | ↑ Buy | 26,472,492 | $0.39 | $10.3M | Direct | Dec 9, 2009 (0d) |
| Mar 11, 2008 | ROIA | ↑ Buy | 10,000 | $1.21 | $12K | Direct | Mar 13, 2008 (2d) |
| Jun 9, 2005 | BER | ↓ Sell | 4,964 | $35.05 | $174K | Direct | Jun 10, 2005 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other PFE insiders
Open-market trades in the last 12 months
About Ronald E Blaylock's insider trades
Ronald E Blaylock is a director at Pfizer (PFE). Since Jun 9, 2005, Ronald has reported 6 open-market purchases worth $12.3M and 12 sales worth $4.6M on SEC Form 4. In the last 12 months: 1 buy ($999K).
Their filings also include grants and awards (63 filings), option exercises (4 filings), gifts (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PFE insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.